Literature DB >> 28067912

Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease.

James C Lee1, Daniele Biasci1, Rebecca Roberts2, Richard B Gearry2, John C Mansfield3, Tariq Ahmad4, Natalie J Prescott5, Jack Satsangi6, David C Wilson7, Luke Jostins8, Carl A Anderson9, James A Traherne10, Paul A Lyons1, Miles Parkes1, Kenneth G C Smith1.   

Abstract

For most immune-mediated diseases, the main determinant of patient well-being is not the diagnosis itself but instead the course that the disease takes over time (prognosis). Prognosis may vary substantially between patients for reasons that are poorly understood. Familial studies support a genetic contribution to prognosis, but little evidence has been found for a proposed association between prognosis and the burden of susceptibility variants. To better characterize how genetic variation influences disease prognosis, we performed a within-cases genome-wide association study in two cohorts of patients with Crohn's disease. We identified four genome-wide significant loci, none of which showed any association with disease susceptibility. Conversely, the aggregated effect of all 170 disease susceptibility loci was not associated with disease prognosis. Together, these data suggest that the genetic contribution to prognosis in Crohn's disease is largely independent of the contribution to disease susceptibility and point to a biology of prognosis that could provide new therapeutic opportunities.

Entities:  

Mesh:

Year:  2017        PMID: 28067912      PMCID: PMC5730041          DOI: 10.1038/ng.3755

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   41.307


  52 in total

1.  Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark.

Authors:  Tine Jess; Lene Riis; Ida Vind; Karen Vanessa Winther; Sixten Borg; Vibeke Binder; Ebbe Langholz; Ole Østergaard Thomsen; Pia Munkholm
Journal:  Inflamm Bowel Dis       Date:  2007-04       Impact factor: 5.325

2.  A Bayesian measure of the probability of false discovery in genetic epidemiology studies.

Authors:  Jon Wakefield
Journal:  Am J Hum Genet       Date:  2007-07-03       Impact factor: 11.025

3.  T-cell activation in HLA-B8, DR3-positive individuals. Early antigen expression defect in vitro.

Authors:  G Candore; D Cigna; M Todaro; R De Maria; G Stassi; C Giordano; C Caruso
Journal:  Hum Immunol       Date:  1995-04       Impact factor: 2.850

4.  Data quality control in genetic case-control association studies.

Authors:  Carl A Anderson; Fredrik H Pettersson; Geraldine M Clarke; Lon R Cardon; Andrew P Morris; Krina T Zondervan
Journal:  Nat Protoc       Date:  2010-08-26       Impact factor: 13.491

5.  Clinical patterns of familial inflammatory bowel disease.

Authors:  J Satsangi; C Grootscholten; H Holt; D P Jewell
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

6.  Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort.

Authors:  R K Weersma; P C F Stokkers; A A van Bodegraven; R A van Hogezand; H W Verspaget; D J de Jong; C J van der Woude; B Oldenburg; R K Linskens; E A M Festen; G van der Steege; D W Hommes; J B A Crusius; C Wijmenga; I M Nolte; G Dijkstra
Journal:  Gut       Date:  2008-09-29       Impact factor: 23.059

7.  Clustering of disease features within 512 multicase rheumatoid arthritis families.

Authors:  Damini Jawaheer; Raymond F Lum; Christopher I Amos; Peter K Gregersen; Lindsey A Criswell
Journal:  Arthritis Rheum       Date:  2004-03

8.  A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis.

Authors:  Leonid Padyukov; Mark Seielstad; Rick T H Ong; Bo Ding; Johan Rönnelid; Maria Seddighzadeh; Lars Alfredsson; Lars Klareskog
Journal:  Ann Rheum Dis       Date:  2010-12-14       Impact factor: 19.103

9.  The UK10K project identifies rare variants in health and disease.

Authors:  Klaudia Walter; Josine L Min; Jie Huang; Lucy Crooks; Yasin Memari; Shane McCarthy; John R B Perry; ChangJiang Xu; Marta Futema; Daniel Lawson; Valentina Iotchkova; Stephan Schiffels; Audrey E Hendricks; Petr Danecek; Rui Li; James Floyd; Louise V Wain; Inês Barroso; Steve E Humphries; Matthew E Hurles; Eleftheria Zeggini; Jeffrey C Barrett; Vincent Plagnol; J Brent Richards; Celia M T Greenwood; Nicholas J Timpson; Richard Durbin; Nicole Soranzo
Journal:  Nature       Date:  2015-09-14       Impact factor: 49.962

10.  Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study.

Authors:  Isabelle Cleynen; Gabrielle Boucher; Luke Jostins; L Philip Schumm; Sebastian Zeissig; Tariq Ahmad; Vibeke Andersen; Jane M Andrews; Vito Annese; Stephan Brand; Steven R Brant; Judy H Cho; Mark J Daly; Marla Dubinsky; Richard H Duerr; Lynnette R Ferguson; Andre Franke; Richard B Gearry; Philippe Goyette; Hakon Hakonarson; Jonas Halfvarson; Johannes R Hov; Hailang Huang; Nicholas A Kennedy; Limas Kupcinskas; Ian C Lawrance; James C Lee; Jack Satsangi; Stephan Schreiber; Emilie Théâtre; Andrea E van der Meulen-de Jong; Rinse K Weersma; David C Wilson; Miles Parkes; Severine Vermeire; John D Rioux; John Mansfield; Mark S Silverberg; Graham Radford-Smith; Dermot P B McGovern; Jeffrey C Barrett; Charlie W Lees
Journal:  Lancet       Date:  2015-10-18       Impact factor: 202.731

View more
  83 in total

Review 1.  Genetic Risk Scores for Type 1 Diabetes Prediction and Diagnosis.

Authors:  Maria J Redondo; Richard A Oram; Andrea K Steck
Journal:  Curr Diab Rep       Date:  2017-10-28       Impact factor: 4.810

Review 2.  Rare and common variant discovery in complex disease: the IBD case study.

Authors:  Guhan R Venkataraman; Manuel A Rivas
Journal:  Hum Mol Genet       Date:  2019-11-21       Impact factor: 6.150

Review 3.  Redefining the IBDs using genome-scale molecular phenotyping.

Authors:  Terrence S Furey; Praveen Sethupathy; Shehzad Z Sheikh
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-05       Impact factor: 46.802

4.  IBD: Genetic differences in Crohn's disease susceptibility and outcome.

Authors:  Kajari Mondal; Subra Kugathasan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-03-08       Impact factor: 46.802

5.  LRRK2 but not ATG16L1 is associated with Paneth cell defect in Japanese Crohn's disease patients.

Authors:  Ta-Chiang Liu; Takeo Naito; Zhenqiu Liu; Kelli L VanDussen; Talin Haritunians; Dalin Li; Katsuya Endo; Yosuke Kawai; Masao Nagasaki; Yoshitaka Kinouchi; Dermot Pb McGovern; Tooru Shimosegawa; Yoichi Kakuta; Thaddeus S Stappenbeck
Journal:  JCI Insight       Date:  2017-03-23

6.  Genetic and environmental factors drive personalized medicine for Crohn's disease.

Authors:  Shigeru Oshima; Mamoru Watanabe
Journal:  J Clin Invest       Date:  2018-10-15       Impact factor: 14.808

Review 7.  Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis.

Authors:  Eric Gracey; Lars Vereecke; Dermot McGovern; Mareike Fröhling; Georg Schett; Silvio Danese; Martine De Vos; Filip Van den Bosch; Dirk Elewaut
Journal:  Nat Rev Rheumatol       Date:  2020-07-13       Impact factor: 20.543

8.  Interaction between smoking and ATG16L1T300A triggers Paneth cell defects in Crohn's disease.

Authors:  Ta-Chiang Liu; Justin T Kern; Kelli L VanDussen; Shanshan Xiong; Gerard E Kaiko; Craig B Wilen; Michael W Rajala; Roberta Caruso; Michael J Holtzman; Feng Gao; Dermot Pb McGovern; Gabriel Nunez; Richard D Head; Thaddeus S Stappenbeck
Journal:  J Clin Invest       Date:  2018-10-15       Impact factor: 14.808

Review 9.  Updates in Lupus Genetics.

Authors:  Yun Deng; Betty P Tsao
Journal:  Curr Rheumatol Rep       Date:  2017-10-05       Impact factor: 4.592

10.  IBD in 2017: Development of therapy for and prediction of IBD - getting personal.

Authors:  Raja Atreya; Britta Siegmund
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-12-06       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.